To test this hypothesis, we utilised 12 KRAS/NRAS/BRAFV600 WT cell lines, representing both cetuximab sensitive and resistant cells, and patient-derived samples that were isolated from serous effusions of patients with KRAS/NRAS/BRAFV600 WT CRC, who were resistant to cetuximab. The gene discussed is KRAS; the disease is colorectal carcinoma.